Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CEO Sanjiv Patel sold 75,324 shares of the company's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $3.70, for a total transaction of $278,698.80. Following the completion of the transaction, the chief executive officer now directly owns 883,089 shares in the company, valued at approximately $3,267,429.30. The trade was a 7.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Sanjiv Patel also recently made the following trade(s):
- On Tuesday, February 11th, Sanjiv Patel sold 140,182 shares of Relay Therapeutics stock. The stock was sold at an average price of $3.85, for a total value of $539,700.70.
- On Wednesday, January 22nd, Sanjiv Patel sold 125,000 shares of Relay Therapeutics stock. The shares were sold at an average price of $4.80, for a total value of $600,000.00.
- On Monday, December 16th, Sanjiv Patel sold 100,000 shares of Relay Therapeutics stock. The stock was sold at an average price of $5.00, for a total value of $500,000.00.
Relay Therapeutics Stock Up 5.3 %
Shares of Relay Therapeutics stock opened at $3.96 on Friday. The company has a fifty day moving average of $4.46 and a 200-day moving average of $5.81. Relay Therapeutics, Inc. has a 52-week low of $3.50 and a 52-week high of $11.16.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC lifted its stake in shares of Relay Therapeutics by 6.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 41,203 shares of the company's stock valued at $292,000 after acquiring an additional 2,547 shares during the last quarter. Martingale Asset Management L P increased its stake in Relay Therapeutics by 3.5% in the 4th quarter. Martingale Asset Management L P now owns 80,371 shares of the company's stock worth $331,000 after purchasing an additional 2,700 shares during the period. Ameritas Investment Partners Inc. lifted its position in Relay Therapeutics by 41.9% in the fourth quarter. Ameritas Investment Partners Inc. now owns 12,730 shares of the company's stock valued at $52,000 after purchasing an additional 3,760 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its stake in shares of Relay Therapeutics by 160.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 6,500 shares of the company's stock valued at $27,000 after purchasing an additional 4,000 shares during the period. Finally, Invesco Ltd. grew its holdings in shares of Relay Therapeutics by 4.6% in the fourth quarter. Invesco Ltd. now owns 119,417 shares of the company's stock worth $492,000 after purchasing an additional 5,261 shares during the last quarter. 96.98% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on RLAY. JMP Securities reaffirmed a "market outperform" rating and issued a $21.00 target price on shares of Relay Therapeutics in a research note on Thursday, December 12th. Leerink Partners lowered their price objective on shares of Relay Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research report on Wednesday, December 4th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of Relay Therapeutics in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $20.50.
View Our Latest Stock Report on RLAY
Relay Therapeutics Company Profile
(
Get Free Report)
Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
